Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
José Luis Piñana 1 , Lourdes Vázquez 2 , Rodrigo Martino 3 , Rafael de la Cámara 4 , Anna Sureda 5 , Rebeca Rodríguez-Veiga 6 , Ana Garrido 3 , Jorge Sierra 3 , José-María Ribera 7 , Anna Torrent 7 , María Victoria Mateos 2 , Javier de la Rubia 6 , Mar Tormo 1 , María Díez-Campelo 2 , Valentín García-Gutiérrez 8 , Alberto Álvarez-Larrán 9 , Juan-Manuel Sancho 8 , Alejandro MartínGarcía-Sancho 2 , Lucrecia Yañez 10 , José Antonio Pérez Simón 11 , Pere Barba 12 , Pau Abrisqueta 12 , Iván Álvarez-Twose 13 , Santiago Bonanad 6 , Ramón Lecumberri 14 15 , Isabel Ruiz-Camps 16 , David Navarro 17 , José-Ángel Hernández-Rivas 18 , Ángel Cedillo 1 , Ramón García-Sanz 2 , Francesc Bosch 12
In the midst of the COVID-19 pandemic, different vaccines in front of SARS-CoV-2 have been approved and administered in different vulnerable populations. As patients with cancer were excluded from pivotal trials of vaccination, little is known on their immunogenic response to these vaccines, particularly in patients with severely impaired immune system. In response to that uncertainty, the Spanish Society of Hematology and Hemotherapy launched an initiative aimed to provide recommendations for vaccination of the main hematological conditions.
This document is based on the available information on COVID-19 outcomes, prior knowledge on vaccination in hematological patients, recent published data on serological response in oncohematological patients and expert opinions. New information about SARS-CoV-2 vaccination will be gathered in the near future, providing new scientific grounds to delineate the most adequate management of vaccination in patients with hematological diseases.
The current limited data on SARS-CoV-2 vaccines in hematological patients represents a major limitation of this expert consensus opinion. In fact, the speed in which this field evolves may reduce their validity in the near future.